title: The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity.
abstract: BACKGROUND
  Immunological alterations are implicated in the increased prevalence of high-grade squamous intraepithelial lesions (HG-SIL) and persistent human papillomavirus (HPV) infection. This study evaluated the expression of CD4, CD8, CD25 (IL-2Ralpha) and CD28 antigens from SIL biopsies, stratified by HIV status and HPV-type. Biopsies specimens from 82 (35 HIV+) women with a normal cervix, low-grade (LG-SIL) or high-grade lesions (HG-SIL) were studied. CD molecule expression was evaluated by immunohistochemistry and HPV detection/typing performed using PCR techniques.
  
  
  RESULTS
  CD4 stromal staining was increased in patients with HPV18. Women with HPV16 infection showed decreased: a) CD8 and CD25 stromal staining, b) CD25 staining in LG-SIL epithelium and in HG-SIL stroma. In HIV- women samples, CD28 epithelial staining and CD8 stromal staining surrounding metaplastic epithelium were less intense and even absent, as compared to HIV+ women. Both epithelial and stromal CD8 staining was more intense in the HG-SIL/HIV+ group than in the HG-SIL/HIV- group. Positive correlations were observed between CD4/CD25, CD4/CD28 and CD25/CD28 in the stroma and CD25/CD28 in the epithelium.
  
  
  CONCLUSIONS
  HIV status and HPV-type may influence the lymphomononuclear cell profile present in the spectrum of cervical lesions. The knowledge of the infiltrating cell profile in cervical tumours may help the development of specific anti-tumoural strategies.
authors.affiliation: Division of Clinical Immunology, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. epigin@uol.com.br
authors.forename: Maria Alice G
authors.initials: MA
authors.lastname: Gonçalves
authors.forename: Edson G
authors.initials: EG
authors.lastname: Soares
authors.forename: Eduardo A
authors.initials: EA
authors.lastname: Donadi
references.citation: Genes Dev. 1998 Jul 1;12(13):2061-72
references.pmid: 9649509
references.citation: Science. 1988 Jan 29;239(4839):487-91
references.pmid: 2448875
references.citation: Immunol Today. 1997 Oct;18(10):493-7
references.pmid: 9357142
references.citation: Eur J Obstet Gynecol Reprod Biol. 2004 Jun 15;114(2):221-7
references.pmid: 15140519
references.citation: Clin Exp Immunol. 1998 Aug;113(2):183-9
references.pmid: 9717966
references.citation: Oncogene. 2000 Jan 27;19(4):514-25
references.pmid: 10698521
references.citation: Lab Invest. 1988 Feb;58(2):141-9
references.pmid: 2448545
references.citation: Clin Exp Immunol. 1999 Apr;116(1):33-40
references.pmid: 10209502
references.citation: Hum Immunol. 1997 Aug-Sep;56(1-2):39-48
references.pmid: 9455492
references.citation: Cancer. 1995 Oct 15;76(8):1411-5
references.pmid: 8620416
references.citation: Cancer. 2001 Apr 25;93(2):111-4
references.pmid: 11309776
references.citation: Immunotechnology. 1996 Nov;2(4):241-51
references.pmid: 9373306
references.citation: Cytokine. 1995 Aug;7(6):568-74
references.pmid: 8580374
references.citation: Int J Cancer. 2002 Feb 10;97(5):654-9
references.pmid: 11807793
references.citation: Int J Cancer. 1994 Feb 1;56(3):314-9
references.pmid: 8314316
references.citation: Scand J Immunol. 2002 Aug;56(2):204-11
references.pmid: 12121440
references.citation: Cancer. 1999 Oct 15;86(8):1537-43
references.pmid: 10526283
references.citation: Ciba Found Symp. 1994;187:21-32; discussion 32-44
references.pmid: 7796671
references.citation: Ann Biol Clin (Paris). 1998 May-Jun;56(3):267-76
references.pmid: 9754259
references.citation: Cancer Res. 1996 Sep 1;56(17):3967-74
references.pmid: 8752165
references.citation: Gynecol Oncol. 2000 Mar;76(3):315-9
references.pmid: 10684703
references.citation: J Immunol. 1994 Jul 1;153(1):412-20
references.pmid: 7515928
references.citation: Oncogene. 2000 Jul 6;19(29):3235-44
references.pmid: 10918580
references.citation: J Pathol. 1998 Mar;184(3):283-90
references.pmid: 9614381
references.citation: Cancer Res. 1998 Apr 15;58(8):1700-6
references.pmid: 9563486
references.citation: J Gen Virol. 1996 Jul;77 ( Pt 7):1585-93
references.pmid: 8758003
references.citation: Biotechniques. 1994 Nov;17(5):914-21
references.pmid: 7840973
references.citation: Diagn Mol Pathol. 1996 Sep;5(3):220-4
references.pmid: 8866237
references.citation: Cancer Res. 1994 Dec 1;54(23):6243-8
references.pmid: 7954473
references.citation: Int J Cancer. 2000 Oct 1;88(1):92-8
references.pmid: 10962445
references.citation: J Immunol. 2001 Sep 1;167(5):2972-8
references.pmid: 11509647
references.citation: Curr Opin Obstet Gynecol. 2009 Feb;21(1):54-9
references.pmid: 19125004
references.citation: J Gen Virol. 1990 Jan;71 ( Pt 1):173-81
references.pmid: 2154534
references.citation: Clin Exp Immunol. 1997 Mar;107(3):440-7
references.pmid: 9067514
references.citation: Int J Cancer. 1994 Oct 15;59(2):225-34
references.pmid: 7523315
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482
references.citation: J Immunol. 1999 Dec 15;163(12):6762-8
references.pmid: 10586075
references.citation: Int J Cancer. 1994 Jun 15;57(6):805-13
references.pmid: 8206676